EG20747A - Method for preparing galanthamine derivatives as acetylcholinesterase inhibitors - Google Patents
Method for preparing galanthamine derivatives as acetylcholinesterase inhibitorsInfo
- Publication number
- EG20747A EG20747A EG63794A EG63794A EG20747A EG 20747 A EG20747 A EG 20747A EG 63794 A EG63794 A EG 63794A EG 63794 A EG63794 A EG 63794A EG 20747 A EG20747 A EG 20747A
- Authority
- EG
- Egypt
- Prior art keywords
- acetylcholinesterase inhibitors
- galanthamine derivatives
- alkylaminocarbonyloxy
- preparing
- preparing galanthamine
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical class O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 1
- 125000005195 alkyl amino carbonyloxy group Chemical group 0.000 abstract 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/137,443 US6323196B1 (en) | 1993-10-15 | 1993-10-15 | Galanthamine derivatives as acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EG20747A true EG20747A (en) | 2000-01-31 |
Family
ID=22477457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EG63794A EG20747A (en) | 1993-10-15 | 1994-10-12 | Method for preparing galanthamine derivatives as acetylcholinesterase inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6323196B1 (pl) |
| EP (2) | EP1020469A3 (pl) |
| JP (1) | JP2718637B2 (pl) |
| KR (1) | KR100189043B1 (pl) |
| CN (1) | CN1039011C (pl) |
| AT (1) | ATE201687T1 (pl) |
| AU (1) | AU679560B2 (pl) |
| CA (1) | CA2118171C (pl) |
| CZ (1) | CZ283561B6 (pl) |
| DE (1) | DE69427332T2 (pl) |
| DK (1) | DK0648771T3 (pl) |
| EG (1) | EG20747A (pl) |
| ES (1) | ES2158876T3 (pl) |
| FI (1) | FI108724B (pl) |
| GR (1) | GR3036068T3 (pl) |
| IL (1) | IL111273A (pl) |
| NO (1) | NO307463B1 (pl) |
| NZ (1) | NZ264681A (pl) |
| PL (1) | PL177754B1 (pl) |
| PT (1) | PT648771E (pl) |
| RO (1) | RO114132B1 (pl) |
| RU (1) | RU2113438C1 (pl) |
| TW (1) | TW375615B (pl) |
| ZA (1) | ZA948060B (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
| AU1738800A (en) | 1998-11-23 | 2000-06-13 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
| KR100437105B1 (ko) | 1998-12-24 | 2004-06-23 | 얀센 파마슈티카 엔.브이. | 방출 조절형 갈란타민 조성물 |
| EP2311463A1 (en) * | 1999-12-10 | 2011-04-20 | Bonnie M. Davis | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| PL202463B1 (pl) | 2000-03-31 | 2009-06-30 | Sanochemia Pharmazeutika Ag | Pochodne galantaminy, sposób ich wytwarzania, środek leczniczy zawierajacy te pochodne, zastosowanie pochodnej galantaminy do wytwarzania środków leczniczych, sposób wytwarzania środków leczniczych oraz sposób oddzielania (+)- i (-)-izomerów |
| US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
| WO2004041281A1 (en) * | 2002-11-01 | 2004-05-21 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
| US20050048543A1 (en) * | 2003-07-11 | 2005-03-03 | Jeroen Aerssens | CHRNA2 genetic markers associated with galantamine response |
| WO2005042762A2 (en) * | 2003-10-28 | 2005-05-12 | Genaissance Pharmaceuticals, Inc. | Lrpap1 genetic markers associated with galantamine response |
| US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
| US7250258B2 (en) * | 2003-12-15 | 2007-07-31 | Pgxhealth Llc | CDK5 genetic markers associated with galantamine response |
| WO2005065662A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Solid dosage formulations of galantamine |
| WO2005065661A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Immediate, controlled and sustained release formulations of galanthamine |
| JPWO2006004201A1 (ja) * | 2004-07-01 | 2008-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経再生促進剤 |
| WO2006124584A2 (en) * | 2005-05-13 | 2006-11-23 | Alza Corporation | Multilayer drug delivery system with barrier against reservoir material flow |
| US20080188510A1 (en) * | 2005-05-23 | 2008-08-07 | Eisai R & D Management Co., Ltd. | Novel methods using zonisamide |
| EP1777222A1 (en) * | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
| WO2007035941A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal galantamine delivery system |
| KR100786371B1 (ko) * | 2006-12-07 | 2007-12-17 | 한국화학연구원 | 갈란타민의 제조방법 |
| CN102007129B (zh) | 2008-04-14 | 2014-05-07 | 神经动力生命科学公司 | 用作治疗人类脑疾病的前药的雪花胺衍生物 |
| EP2456434A1 (en) * | 2009-07-23 | 2012-05-30 | Shire LLC | Galantamine amino acid and peptide prodrugs and uses thereof |
| US12551491B1 (en) * | 2025-07-23 | 2026-02-17 | Alpha Cognition Inc. | Dosage regimens for benzgalantamine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL122665B1 (en) | 1978-11-21 | 1982-08-31 | Edinen Zentar Chim | Process for preparing novel dienones of narvedine type and their derivatives |
| US4663318A (en) | 1986-01-15 | 1987-05-05 | Bonnie Davis | Method of treating Alzheimer's disease |
| US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| JP2755403B2 (ja) * | 1987-05-04 | 1998-05-20 | デイービス、ボニー | アルツハイマー病の治療のための化合物 |
| NL8800350A (nl) | 1988-02-12 | 1989-09-01 | Stichting Biomedical Research | Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen. |
| EP0584185B1 (en) * | 1991-05-14 | 1999-08-11 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| US5231093A (en) * | 1991-10-01 | 1993-07-27 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
| US5153193A (en) | 1991-10-01 | 1992-10-06 | Hoechst-Roussel Pharmaceuticals Incorporated | Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs |
-
1993
- 1993-10-15 US US08/137,443 patent/US6323196B1/en not_active Expired - Lifetime
-
1994
- 1994-10-10 DE DE69427332T patent/DE69427332T2/de not_active Expired - Lifetime
- 1994-10-10 DK DK94115960T patent/DK0648771T3/da active
- 1994-10-10 AT AT94115960T patent/ATE201687T1/de active
- 1994-10-10 PT PT94115960T patent/PT648771E/pt unknown
- 1994-10-10 EP EP00107569A patent/EP1020469A3/en not_active Withdrawn
- 1994-10-10 ES ES94115960T patent/ES2158876T3/es not_active Expired - Lifetime
- 1994-10-10 EP EP94115960A patent/EP0648771B1/en not_active Expired - Lifetime
- 1994-10-12 EG EG63794A patent/EG20747A/xx active
- 1994-10-13 IL IL111273A patent/IL111273A/en not_active IP Right Cessation
- 1994-10-13 RU RU94036761A patent/RU2113438C1/ru active
- 1994-10-13 FI FI944822A patent/FI108724B/fi not_active IP Right Cessation
- 1994-10-13 NZ NZ264681A patent/NZ264681A/en not_active IP Right Cessation
- 1994-10-14 AU AU75812/94A patent/AU679560B2/en not_active Expired
- 1994-10-14 TW TW083109528A patent/TW375615B/zh not_active IP Right Cessation
- 1994-10-14 NO NO943894A patent/NO307463B1/no not_active IP Right Cessation
- 1994-10-14 CN CN94117061A patent/CN1039011C/zh not_active Expired - Lifetime
- 1994-10-14 ZA ZA948060A patent/ZA948060B/xx unknown
- 1994-10-14 CA CA002118171A patent/CA2118171C/en not_active Expired - Lifetime
- 1994-10-14 CZ CZ942547A patent/CZ283561B6/cs not_active IP Right Cessation
- 1994-10-14 KR KR1019940026304A patent/KR100189043B1/ko not_active Expired - Lifetime
- 1994-10-14 RO RO94-01668A patent/RO114132B1/ro unknown
- 1994-10-14 PL PL94305455A patent/PL177754B1/pl unknown
- 1994-10-17 JP JP6250776A patent/JP2718637B2/ja not_active Expired - Fee Related
-
2001
- 2001-06-19 GR GR20010400911T patent/GR3036068T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GR3036068T3 (en) | Galanthamine derivatives, a process for their preparation and their use as medicaments. | |
| CA2322944A1 (en) | Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors | |
| TW254943B (pl) | ||
| TW264477B (pl) | ||
| EG20472A (en) | Process for preparing of golanthamine derivatives a acitylcholinesterase inhibitors | |
| AU3744397A (en) | Total synthesis of antitumor acylfulvenes | |
| AU2722095A (en) | Novel pyrrolocarbazoles | |
| AU586867B2 (en) | Biocidal mixture | |
| AU1765288A (en) | Cycloalkylamides of (8beta)-1-isopropyl-6-(substituted) ergolines | |
| EP0555479A4 (pl) | ||
| HU913900D0 (en) | Method for producing 2-halogen-pyrrhole-3-carbonitrile derivatives | |
| EP1028118A4 (en) | METHOD FOR PRODUCING 3-CEPHEM COMPOUNDS | |
| ES2144327T3 (es) | Procedimiento para preparar un compuesto de 2-cianobifenilo. | |
| NZ233196A (en) | Process for preparing glutaric acid derivatives and 2-alkoxycarbonylalkyl cyclohexanone derivatives | |
| EP0590681A3 (en) | A process for the preparation of aminothiadiazolylacetyl halide derivatives | |
| EP0573659A4 (en) | Pyrazolothiazolopyrimidine derivative | |
| TW239123B (pl) |